17-beta-hydroxysteroid dehydrogenase deficiency medical therapy
|
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
|
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17-beta-hydroxysteroid dehydrogenase deficiency medical therapy On the Web |
|
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency medical therapy |
|
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency medical therapy |
|
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency medical therapy |
|
17-beta-hydroxysteroid dehydrogenase deficiency medical therapy in the news |
|
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency medical therapy |
|
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Overview
If the diagnosis of 17 beta hydroxysteroid dehydrogenase deficiency is made at birth, gender assignment should be discussed, depending on the expected result of virilization genioplasty.
Medical therapy
- If the diagnosis of 17 beta hydroxysteroid dehydrogenase deficiency is made at birth, gender assignment should be discussed, depending on the expected result of virilization genioplasty.
- Affected individuals who raised as male may virilize on their own or with the help of testosterone treatment.
- In female patients who underwent gonadectomy, appropriate intervention with estrogen therapy should be introduced at the time of puberty to induce secondary sexual characteristics.
- Patients with 17 beta hydroxysteroid dehydrogenase deficiency have moderate risk of germ cell tumor and close monitoring is required.
- Gender identity starts to develop around age 3 but it is not clear when it can be reliably assessed.
- The patient and family will require psychological counseling to accept the diagnosis and the infertility that follows it.[1]